XML 50 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating activities:    
Net loss $ (146,829,000) $ (129,281,000)
Adjustments to reconcile net loss to net cash used for operating activities:    
Stock-based compensation expense 40,312,000 23,572,000
Depreciation and amortization 1,480,000 1,093,000
Amortization of debt discount 780,000 654,000
Realized gain on short-term investments (8,000) 0
Accretion of discount on short-term investments (3,264,000) (1,920,000)
Impairment on property and equipment 80,000  
Loss on disposal of property and equipment 53,000 3,000
Change in operating assets and liabilities:    
Accounts receivable (2,303,000) (11,759,000)
Prepaid expenses and other assets (5,549,000) (6,505,000)
Inventory 14,860,000 (21,502,000)
Accounts payable (15,236,000) (9,125,000)
Accrued clinical and manufacturing liabilities 1,603,000 (12,639,000)
Accrued payroll and employee liabilities (3,263,000) (403,000)
Other accrued liabilities 19,681,000 9,494,000
Net cash used for operating activities (97,603,000) (158,318,000)
Investing activities:    
Purchases of short-term investments (287,579,000) (400,382,000)
Maturities and sales of short-term investments 395,406,000 119,200,000
Purchases of property and equipment (3,251,000) (5,696,000)
Net cash provided by (used for) investing activities 104,576,000 (286,878,000)
Financing activities:    
Payments of stock issuance costs (110,000)  
Net proceeds from sale of common stock   363,128,000
Repayment of promissory note payable to related party   (25,000,000)
Proceeds from stock option exercises 20,239,000 15,771,000
Proceeds from purchases under the Employee Stock Purchase Plan 1,170,000 648,000
Net cash provided by financing activities 21,299,000 354,547,000
Net increase (decrease) in cash and cash equivalents 28,272,000 (90,649,000)
Cash and cash equivalents at beginning of year 31,836,000 144,583,000
Cash and cash equivalents at end of period $ 60,108,000 53,934,000
Supplemental disclosure of cash flow information:    
Interest paid   1,183,000
Cumulative effect of adoption of new accounting standard   $ 1,574,000